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Introduction: The aim of this study is to analyze all metastatic (M) 
categories of the current tumor, node, and metastasis (TNM) clas-
siﬁcation of lung cancer with the objective of providing suggestions 
for modiﬁcations of the M component in the next edition of the TNM 
classiﬁcation for lung cancer.
Methods: The new International Association for the Study of Lung 
Cancer lung cancer database was created from 94,708 patients diag-
nosed as having lung cancer between 1999 and 2010. Including fur-
ther patients submitted through the electronic data capture system 
to Cancer Research and Biostatistics until 2012, all together 1059 
non–small-cell lung cancer cases were available for a detailed analy-
sis of the clinical M categories. Overall survival was calculated using 
the Kaplan–Meier method, and prognosis was assessed using a Cox 
proportional hazards regression analysis.
Results: No signiﬁcant differences were found among the M1a 
(metastases within the chest cavity) descriptors. However, when M1b 
(distant metastases outside the chest cavity) were assessed according 
to the number of metastases, tumors with a single metastasis in a 
single organ had signiﬁcantly better prognosis than those with mul-
tiple metastases in one or several organs.
Conclusions: In this revision of the TNM classiﬁcation, cases with 
pleural/pericardial effusions, contralateral/bilateral lung nodules, 
contralateral/bilateral pleural nodules, or a combination of multiple 
of these parameters should continue to be grouped as M1a category. 
Single metastatic lesions in a single distant organ should be newly 
designated to the M1b category. Multiple lesions in a single organ 
or multiple lesions in multiple organs should be reclassiﬁed as M1c 
category. This new division can serve as a ﬁrst step into providing 
rational deﬁnitions for an oligometastatic disease stage in non–small-
cell lung cancer in the future.
Key Words: Lung cancer, Non–small-cell lung cancer, Staging, 
Metastases.
(J Thorac Oncol. 2015;10: 1515–1522)
The baseline objective of this investigation was to explore if the M categories developed for the 7th edition of the 
tumor, node, and metastasis (TNM) classiﬁcation for lung 
cancer, and proposed by the International Association for 
the Study of Lung Cancer (IASLC) accurately reflect patient 
prognosis in the data set prospectively submitted to form the 
new IASLC TNM staging classiﬁcation database.1,2 Since the 
7th edition TNM staging classiﬁcation for non–small-cell lung 
cancer (NSCLC) was proposed in 2007, several innovative 
developments in diagnosis, imaging, and treatment of NSCLC 
have been added to our general lung cancer management port-
folio.1,2 Especially, since the last database was derived from 
patients diagnosed and treated between 1990 and 2000, posi-
tron emission tomography (PET) staging has entered into com-
mon diagnostic practice (as opposed to the database for the 7th 
edition, which was based on patients diagnosed and treated 
between 1990 and 2000).3 Minimally invasive endoscopic and 
surgical methods for handling small pleural and pulmonary 
lesions both diagnostically and therapeutically have found 
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their way into staging and treatment algorithms.4,5 Signiﬁcant 
improvements have been made in precision radiotherapy 
techniques such as brain or body stereotactic radiotherapy.6,7 
Systemic treatments including molecular-targeted agents 
in selected adenocarcinoma patients with a driver mutation 
and maintenance chemotherapy strategies have signiﬁcantly 
improved systemic control in some of the patients.8,9 With this 
in mind, we may have to reconsider some of the existing stag-
ing and therapeutic algorithms for several of the disease stages 
in NSCLC in the future.10–12 But the metastatic disease status 
has to be redeﬁned keeping in mind ongoing stage migration 
(PET, brain computed tomography [CT], and magnetic reso-
nance imaging) and new possibilities for deﬁnitive treatment 
of single metastatic lesions (surgery, stereotactic body radia-
tion therapy).13 This is the general scenario based on which 
we should critically analyze the new prospectively collected 
IASLC staging database for the development of proposals for 
the new M descriptors of the 8th TNM classiﬁcation.1 Based 
on early expert recommendations coming from input of the 
IASLC Staging and Prognostic Factor Committee, docu-
mentation for the prospective data set had included several 
parameters to work on a potentially relevant revision of the 
M category.1 This information exceeded that available for the 
generation of the 7th edition of the lung cancer TNM staging 
classiﬁcation. Here, we will report the overall ﬁndings gener-
ated from this existing database and propose possible lines of 
future developments based on prospective documentation of 
parameters for the next database to come.
MATERIAL AND METHODS
Population Analyzed for the M Descriptors
The process for data acquisition and analysis of the IASLC 
lung cancer database has already been described in detail in the 
introduction manuscript to the new staging initiative and the 
manuscripts covering the proposals for the T and the N descrip-
tors of the 8th edition of the TNM classiﬁcation.2,14–16 The analy-
sis population of this manuscript includes a subset of patients 
from the IASLC database diagnosed with lung cancer between 
1999 and 2010. Additional patients were submitted to Cancer 
Research and Biostatistics (CRAB) from 2010 to 2012 through 
the electronic data capture (EDC) system and were added to 
this investigation. After restricting to nonresected M1 subjects, 
2411 NSCLC cases were available for analysis (Table 1). This 
includes 1059 cases submitted to CRAB through the EDC, 
1296 cases submitted from the Turkish Thoracic Society, and 56 
cases from an Institutional Registry at Prince Charles Hospital. 
Speciﬁc data elements needed to address the objectives set out 
by the IASLC were primarily available in CRAB’s EDC. Final 
analyses were, therefore, restricted to the EDC cases to avoid 
confounding. The number of cases used in a particular analy-
sis is based on the availability of data to address the analysis 
question. Median follow-up for both M1a and M1b cases in the 
EDC was 29.3 months.
Statistical Methods
General statistical methodology was similar to that 
used for the analysis of the T and the N components of the 
classiﬁcation. Overall survival was measured from the date of 
diagnosis for clinically staged patients. Survival was estimated 
using the Kaplan–Meier method.17 Prognosis was assessed using 
Cox proportional hazards regression analysis.18 All survival and 
regression analyses were performed using SAS version 9.4.19
RESULTS
Prognostic Impact of M1a Descriptors 
from the 7th Edition TNM Classification
This analysis was meant to validate the prognostic 
impact of the M1a descriptors from the current 7th TNM 
staging classiﬁcation when looked at within the data set 
from the 1999 to 2010 prospective staging database.1 This 
included (a) pleural/pericardial effusions, (b) contralateral/
bilateral tumor nodules, (c) pleural/pericardial nodules, or 
(d) the presence of multiple M1a descriptors. Because of 
the lack of information on thoracic tumor nodules in the 
Turkish data, these 81 cases with pleural effusion were 
excluded from the ﬁnal analysis. Complete data information 
was available for this analysis in 324 patients from the EDC. 
Prognosis for the different M1a descriptors turned out to be 
similar (Table 2; Fig. 1). In addition, no prognostic effect 
of single versus multiple M1a descriptors was determined.
Prognostic Impact of 7th Edition M1b Cases
Prospectively collected information in the EDC for the 
metastatic status of the patients was available on single met-
astatic lesions in a single organ site (225 patients), multiple 
metastatic lesions in a single organ (229 patients), and mul-
tiple lesions in multiple organs (247 patients). Overall, the 
site of the metastasis was not prognostic for single or multiple 
lesions within a single organ (Figs. 2 and 3). The aggregated 
data suggested that adrenal metastases might be associated 
with a worse prognosis, but comparisons between data sources 
were not consistent. When the two largest contributors were 
separated out, the negative effect of adrenal metastasis was no 
longer apparent (Figs. 4 and 5). This also held true for multiple 
lesions within a single site (Fig. 6 and 7). Additional data from 
more data sources would certainly be necessary to adequately 
address this important issue. The data suggested that the num-
ber of metastatic lesions may be more prognostic than the num-
ber of organs involved. In addition, prognosis based on a single 
distant metastatic lesion is more similar to M1a (Table 3).
Comparison of the 7th Edition M Categories 
with the Proposed 8th Edition M Categories
The 7th edition M1a and M1b categories separated out 
tumors with different prognosis (Fig. 8). Median survival in 
the M1a category was 11.5 months. For the proposed 8th 
edition of the TNM staging system, we reclassiﬁed M1 cat-
egories as M1a, M1b (single metastatic lesion in one organ), 
and M1c (multiple metastases in either single organ or mul-
tiple organs). When the proposed 8th edition M1a disease, 
single extrathoracic metastasis and multiple extrathoracic 
metastases were evaluated, patients with a single metastatic 
lesion in one organ site (new M1b) showed a prognosis more 
similar to that of patients in the M1a category with a median 
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survival of 11.4 months (Fig. 8). In addition, patients with 
single extrathoracic metastasis had better prognosis than 
those with multiple metastatic lesions in one organ or mul-
tiple organs involved (new M1c).
DISCUSSION
The 7th edition of the TNM classiﬁcation for lung 
cancer laid a speciﬁc focus on separating potentially cura-
tive IIIB stages without proven metastatic M1 disease 
from categories with positive M1 descriptors—M1a and 
M1b—where there was little chance of achieving relevant 
rates of 5-year survival.1,2 Pragmatically, these staging 
categories were meant to address the fundamental differ-
ences in curatively intended treatments—still possible for 
stages IIIA and IIIB—from palliative—purely systemic—
treatments necessary for stage IV.2 The prospectively gener-
ated database from 1999 until 2012 employed for studying 
the M component and presented in this analysis resulted 
from patients submitted to the IASLC/CRAB through the 
EDC.1,2 First of all, the value of the former M1a descriptor 
TABLE 1. Subject Counts by Data Source and 7th edition M Category
7th Edition M Category
Database Type Country Institution M1a M1b
EDC Argentina Hospital Británico de Buenos Aires 2 4
Hospital Universitario Austral 2 2
Hospital Universitario-Fundación Favalor 7
Hospital de Rehabilitación Respiratoria 3 1
Australia Peter MacCallum Cancer Institute 2
Belgium University Hospital Antwerp 15 51
University Hospital Ghent 6 18
Brazil University of Sao Paulo Medical School 2
China Guangdong General Hospital 83 188
France L’Institut Mutualiste Montsouris 3 5
Greece Athens School of Medicine 6 15
Spain Complejo Hospitalario de Ourense 41 83
Complejo Hospitalario La Mancha Centro 9 31
Fundación Jiménez Díaz 18 45
Htal. de la Plana Vila-Real 12 28
Htal. General Universitario de Valencia 1
Htal. General Universitario Gregorio Mar 1
Htal. General Universitario de Albacete 14 42
Htal. Meixoeiro 3 26
Htal. Nuestra Señora de Sonsoles 2 8
Htal. San Pedro Alcántara 12 24
Htal. Severo Ochoa 10 13
Htal. Sierrallana, Sección de Neumología 9 23
Htal. Universitari Joan XXIII 13 10
Htal. Universitario Central de Asturias 6 5
Htal. Universitario La Fe 12 28
Htal. Universitario de Canarias 10 15
Htal. de Sagunto 4
United States Mayo Clinic Rochester 13
NYU Langone Medical Center and Cancer Center 29 37
Penrose Cancer Center 2 5
Subtotal—EDC cases by 7th edition M category 324 735
Subtotal—EDC cases 1059
Consortium Turkey Turkish Thoracic Society 81 1215
Institutional registry Australia Prince Charles Hospital 2 54
Subtotal—All institutions by 7th edition M category 407 2004
Total 2411
EDC, electronic data capture.
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deﬁnition could be conﬁrmed, including patients with pleu-
ral or pericardial effusions, contralateral or bilateral lung 
nodules, or pleural/pericardial nodules into this category.20 
No signiﬁcant differences were noted between the different 
groups deﬁned by these M1a descriptors, and there was also 
no effect noted of single versus multiple descriptors in a 
given cohort. It is not clear, whether these positive ﬁndings 
from clinical staging (e.g., the obviously increased land-
mark survival rates at 1 or 2 years) in comparison with the 
results of the previous edition of the TNM classiﬁcation can 
be explained by stage migration effects based on modern 
imaging methods (PET-CT at least in some of the patients, 
modern CT-scanners or brain magnetic resonance imag-
ing—identifying those with small brain lesions) or can be 
attributed to the possibility that some lesions identiﬁed on 
clinical grounds are not actual sites of malignant involve-
ment.20–22 Future documentation of these parameters should 
in detail register the employed imaging technology in a given 
patient and the necessary cytological/histological conﬁrma-
tion of clinical results from any imaging investigation.
TABLE 2. Prognostic Impact of M1a Descriptors
Variable
Overall Survival
n/N (%) HR (95% CI) P Value
Multiple M1a descriptors 95/324 (29) Reference level
Contra/bilateral tumor nodules 94/324 (29) 0.87 (0.62, 1.24) 0.446
Pleural/pericardial nodules 52/324 (16) 0.81 (0.53, 1.22) 0.314
Pleural/pericardial effusion 83/324 (26) 1.00 (0.70, 1.43) 0.997
P value from score χ2 test in Cox regression.
HR, hazard ratio; 95% CI, 95% conﬁdence interval.
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FIGURE 1. Prognostic impact of M1a descriptors.
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FIGURE 2. Single lesion at single site by organ.
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In recent years, more and more retrospective analyses 
have suggested that there are patients with an “oligometastatic 
disease” status, but these ﬁndings were based primarily on retro-
spective series of selected patients with single metastatic lesions 
in organ sites such as brain, adrenals, or bone, most of them 
from retrospective surgical series.23–29 The current EDC data-
base was able to generate analyses on single metastatic lesion 
in a single organ site, multiple metastases in a single organ, and 
multiple metastases in multiple organs.1,2,20 Interestingly, the 
group with single metastatic lesions in one organ site stood out 
signiﬁcantly from the rest of the population and showed results 
more comparable with those of the M1a descriptor cohort. A 
detailed analysis could not substantiate any organ system that 
showed a signiﬁcantly different prognosis once a single meta-
static lesion was noted. There were, however, some signals that 
single metastatic lesions in the adrenals were a group of signiﬁ-
cantly poor prognosis, but this ﬁnding could not be conﬁrmed 
in all patient groups analyzed. Therefore, currently a single 
metastatic lesion in (a) brain, (b) liver, (c) bone, (d) distant 
lymph node or peritoneum, (e) skin, and (f) adrenal should all 
be grouped together under the M1b descriptor. It may be wise 
in the future for the development of the next revision of the 
TNM classiﬁcation to rigidly document also (a) PET positivity 
(if available) or (b) pathological conﬁrmation of imaging-based 
suspicion of single metastatic lesions. Considering the volume 
effect on prognosis for T descriptors, the diameter of the single 
metastasis and also those of multiple metastases should further 
be prospectively documented.15
The separation of distant metastases into two categories 
was based on the prognostic differences for subjects with a sin-
gle metastatic lesion in a single organ (M1b) versus all other 
patient groups including those with multiple metastatic lesions 
in a single organ and multiple lesions in multiple organs (sub-
sumed under M1c). This is based for the ﬁrst time on a pro-
spective data set to enter the era of rational deﬁnitions for an 
“oligometastatic disease subset” in NSCLC.28,29 Retrospective 
data sets had already speculated that prognostic differences 
exist between patients with single metastatic lesions and 
those with multiple lesions or even those with multiple organs 
involved in the metastatic process.24–29 However, the retrospec-
tive nature of most of these investigations and the differences 
in the individual deﬁnitions of “oligometastatic disease” (span-
ning between one lesion and ﬁve lesions based on the individ-
ual report) as well as resulting different study-related decisions 
on individualized local treatment approaches (surgery, body 
stereotactic radiotherapy, radiotherapy, radiofrequency abla-
tion, etc.) created a heterogeneity that did not result in a clear 
consensus on this important issue, so far.24–30 With the ﬁndings 
presented here from the analysis for the proposed 8th edition M 
categories, we clearly have a rational approach to this unsolved 
issue at hand. Here, again, it may be wise for future prospective 
analyses of patients for the next TNM classiﬁcation to docu-
ment (a) number of metastatic lesions, (b) diameter of indi-
vidual metastatic lesions, and (c) number of involved organs 
with metastatic lesions. In the next staging classiﬁcation, this 
could then potentially develop further subsets of patients with 
individualized more favorable prognosis and in whom curative 
local treatments could be worthwhile testing.
In conclusion, based on the analyses from the given pro-
spective dataset for this revision for the 8th TNM classiﬁca-
tion, we can give the following recommendations.
|
| |
|
|
||
|
||
||||
| |
|
|
|
|
|
| | |
|
||
| |
| |
|
|
|
| | |
| | |
|
| |
| |
|
| |
0 2 4 6 8
Survival, Years
0%
20%
40%
60%
80%
100%
Log-rank p-value = .20
11.8 (8.1, 19.2)11 / 19Liver
9.5 (7.5, 38.3)5 / 8LN/Skin/Perit.
15.4 (11.4, 19.5)19 / 32Brain
17.6 (15.1, 25.7)28 / 50Bone
11.4 (5.7, 16.6)14 / 19Adrenals
in MonthsEvents / N
Median
7th Edition M1b - Single Lesion at Single Site
By Organ
EDC Data Only - China and Others
FIGURE 5. Single lesion at single site by organ—China and 
others.
||
|
|
||
| |
| |
|
|
|
|
|
|
|
|
|
|
0 2 4 6 8
Survival, Years
0%
20%
40%
60%
80%
100%
Log-rank p-value = .02
6.5 (3.1, 11.2)29 / 37Liver
2 (0.1, 9.2)7 / 7LN/Skin/Perit.
3.5 (2.3, 7.7)23 / 24Brain
5.8 (3.6, 9.3)49 / 56Bone
2.4 (1.3, 6.9)9 / 13Adrenals
in MonthsEvents / N
Median
7th Edition M1b - Multiple Lesions at Single Site
By Organ
EDC Data Only - GCCB
FIGURE 6. Multiple lesions at single site by organ—GCCB.
| |
| |
|
|||
|
||
|
|
|
|
||
| | ||
|
|
|
|
|
|
|
0 2 4 6 8
Survival, Years
0%
20%
40%
60%
80%
100%
Log-rank p-value = .10
9.5 (1.7, 36.2)6 / 7Liver
23.2 (9.9, .)3 / 6LN/Skin/Perit.
16.4 (7.1, 27.7)12 / 22Brain
7.4 (6.4, 12.7)40 / 53Bone
NR2 / 4Adrenals
in MonthsEvents / N
Median
7th Edition M1b - Multiple Lesions at Single Site
By Organ
EDC Data Only - China and Others
FIGURE 7. Multiple lesions at single site by organ—China 
and others.
1520 Copyright © 2015 by the International Association for the Study of Lung Cancer
Eberhardt et al. Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015
Recommendations
1.  Maintain the use of the current M1a category, includ-
ing any of the following descriptors: (a) pleural/pericar-
dial effusion, (b) contralateral/bilateral tumor nodules, 
(c) pleural/pericardial nodules, and (d) multiple M1a 
descriptors.
2.  Reclassify the current M1b category for patients with a 
single metastatic lesion in a single organ site, for exam-
ple: (a) brain, (b) liver, (c) bone, (d) distant lymph node/
skin/peritoneum, and (e) adrenal gland. Categorization 
of localization of single lesions in a single organ should 
be prospectively tested based on the individually 
involved organ.
3.  Introduce the new M1c category for patients with (a) 
multiple lesions in a single organ or (b) multiple lesions 
in multiple organs. Comparable with the data now avail-
able for the influence of tumor volume in the T descrip-
tors,2 it is recommended to prospectively register in 
detail (a) the number of metastatic lesions and (b) the 
number of involved organs.
The proposed changes in the M descriptors maintain the 
compatibility with the M descriptors of the previous edition, 
help to better deﬁne “oligometastatic disease,” and improve 
our capacity to indicate prognosis, which is an important 
objective of the TNM classiﬁcation in lung cancer.
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